|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1999-4-16
|
|
pubmed:abstractText |
The combination of paclitaxel and carboplatin is widely used in the treatment of patients with advanced nonsmall cell lung carcinoma. In this Phase I/II study the authors evaluated the feasibility, toxicity, and efficacy of adding a third active antineoplastic agent, gemcitabine, to the paclitaxel/carboplatin combination for the treatment of patients with advanced nonsmall cell lung carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
85
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1269-76
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10189131-Adult,
pubmed-meshheading:10189131-Aged,
pubmed-meshheading:10189131-Aged, 80 and over,
pubmed-meshheading:10189131-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10189131-Carboplatin,
pubmed-meshheading:10189131-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:10189131-Deoxycytidine,
pubmed-meshheading:10189131-Female,
pubmed-meshheading:10189131-Humans,
pubmed-meshheading:10189131-Lung Neoplasms,
pubmed-meshheading:10189131-Male,
pubmed-meshheading:10189131-Middle Aged,
pubmed-meshheading:10189131-Paclitaxel,
pubmed-meshheading:10189131-Survival Rate
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Phase I/II trial of paclitaxel by 1-hour infusion, carboplatin, and gemcitabine in the treatment of patients with advanced nonsmall cell lung carcinoma.
|
|
pubmed:affiliation |
Sarah Cannon-Minnie Pearl Cancer Center, Nashville, Tennessee 37203, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
